Special Issue "Retinopathies: A Challenge for Early Diagnosis, Innovative Treatments and Reliable Follow-Up"
Deadline for manuscript submissions: 15 December 2023 | Viewed by 1876
Interests: eye diseases: neurodegeneration, neuroregeneration
Vision is a complex mechanism involving all the eye structures, the optic nerve, and the brain. Central to the process of vision is the retina, which converts light signals into electric signals that the brain finally interprets as vision. The retina is a thin layer of neural tissue that is unable to regenerate after damage, and it is subjected throughout life to continuous strong oxidative stress, which comes from light and the intense metabolic activities triggered by light in order to produce vision. The main pathologies affecting the retina are diabetic retinopathy, age-related macular degeneration, premature retinopathy, and glaucoma. The latter is often considered a class per se because of a completely different etiology; however, it primarily involves the retinal ganglion cells and so must be included within the group of retinopathies. Such retinopathies are all serious sight-threatening diseases, responsible for the loss of vision of hundreds of millions of individuals worldwide, and for which, however, we still lack reliable and efficient treatments.
In this Special Issue we intend to present the most recent knowledge on the etiology of each one of these pathologies, from which new therapeutic targets should emerge. Additionally, we intend to solicitate a new way to look at them, proposing new therapeutic approaches and innovative treatments, even at the hypothetic level, in order to stimulate and promote new research, hopefully leading to more efficient ways to fight these diseases.
Another point, equally critical, is the way to obtain an early diagnosis of the disease before it becomes clinically relevant in order to start possible non-invasive treatments able to delay progression as much as possible. Connected to this point is the necessity to have reliable, sensitive, short-term assays able to provide an efficient follow-up of treated patients in order to establish their response to the precocious therapies.
Therefore, all contributions to these fields (research papers, reviews, mini-reviews, documented hypotheses) are welcome for publication in this Special Issue.
Dr. Stefania Marsili
Dr. Dario Rusciano
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- early diagnosis
- novel therapies
- short-term follow-up